Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing

Guy W. Neff, Christopher B O'Brien, Robert Cirocco, Marzia Montalbano, Maria de Medina, Phillip Ruiz, Amr S. Khaled, Pablo A. Bejarano, Kamran Safdar, Mary A. Hill, Andreas G. Tzakis, Eugene R Schiff

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The optimal duration of therapy for pegylated interferon combined with ribavirin in recurrent Hepatitis C virus (HCV) following liver transplantation is not known. We wanted to determine if testing for HCV in liver tissue by reverse transcriptase polymerase chain reaction (RT-PCR) was superior in predicting sustained virological response (SVR) in comparison to standard HCV ribonucleic acid (RNA) detection in the serum. All recipients received combination pegylated alpha-2b interferon (1.5 mcg / kg) and ribavirin (200-600mg / d) therapy for at least 48 weeks of therapy and were found to have nondetectable HCV RNA by PCR serum testing at the end of therapy. Sustained virological response (SVR) was defined as nondetectable serum HCV RNA at 6 months post treatment withdrawal. Ten liver transplant recipients were included in the study; mean time from transplantation was 29.2 months. All had nondetectable serum HCV RNA by RT-PCR. In hepatic tissue 7/10 patients HCV RNA was found to be positive by RT-PCR while 3/10 had nondetectable HCV RNA in their liver by RT-PCR. SVR was attained in all 3/10 that were hepatic tissue HCV PCR negative after 12 months of combination therapy. In conclusion, direct detection of HCV RNA by RT-PCR of liver tissue appears to more effectively predict SVR following pegylated interferon and ribavirin therapy than the conventional use of serum.

Original languageEnglish
Pages (from-to)595-598
Number of pages4
JournalLiver Transplantation
Volume10
Issue number5
DOIs
StatePublished - May 1 2004

Fingerprint

Ribavirin
Cell- and Tissue-Based Therapy
Reverse Transcriptase Polymerase Chain Reaction
Hepacivirus
Liver
RNA
Serum
Interferons
Therapeutics
peginterferon alfa-2b
Transplant Recipients
Polymerase Chain Reaction
Liver Transplantation
Transplantation

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. / Neff, Guy W.; O'Brien, Christopher B; Cirocco, Robert; Montalbano, Marzia; de Medina, Maria; Ruiz, Phillip; Khaled, Amr S.; Bejarano, Pablo A.; Safdar, Kamran; Hill, Mary A.; Tzakis, Andreas G.; Schiff, Eugene R.

In: Liver Transplantation, Vol. 10, No. 5, 01.05.2004, p. 595-598.

Research output: Contribution to journalArticle

@article{3e8c0e20c6e04575b7c75d2a12091356,
title = "Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing",
abstract = "The optimal duration of therapy for pegylated interferon combined with ribavirin in recurrent Hepatitis C virus (HCV) following liver transplantation is not known. We wanted to determine if testing for HCV in liver tissue by reverse transcriptase polymerase chain reaction (RT-PCR) was superior in predicting sustained virological response (SVR) in comparison to standard HCV ribonucleic acid (RNA) detection in the serum. All recipients received combination pegylated alpha-2b interferon (1.5 mcg / kg) and ribavirin (200-600mg / d) therapy for at least 48 weeks of therapy and were found to have nondetectable HCV RNA by PCR serum testing at the end of therapy. Sustained virological response (SVR) was defined as nondetectable serum HCV RNA at 6 months post treatment withdrawal. Ten liver transplant recipients were included in the study; mean time from transplantation was 29.2 months. All had nondetectable serum HCV RNA by RT-PCR. In hepatic tissue 7/10 patients HCV RNA was found to be positive by RT-PCR while 3/10 had nondetectable HCV RNA in their liver by RT-PCR. SVR was attained in all 3/10 that were hepatic tissue HCV PCR negative after 12 months of combination therapy. In conclusion, direct detection of HCV RNA by RT-PCR of liver tissue appears to more effectively predict SVR following pegylated interferon and ribavirin therapy than the conventional use of serum.",
author = "Neff, {Guy W.} and O'Brien, {Christopher B} and Robert Cirocco and Marzia Montalbano and {de Medina}, Maria and Phillip Ruiz and Khaled, {Amr S.} and Bejarano, {Pablo A.} and Kamran Safdar and Hill, {Mary A.} and Tzakis, {Andreas G.} and Schiff, {Eugene R}",
year = "2004",
month = "5",
day = "1",
doi = "10.1002/lt.20115",
language = "English",
volume = "10",
pages = "595--598",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing

AU - Neff, Guy W.

AU - O'Brien, Christopher B

AU - Cirocco, Robert

AU - Montalbano, Marzia

AU - de Medina, Maria

AU - Ruiz, Phillip

AU - Khaled, Amr S.

AU - Bejarano, Pablo A.

AU - Safdar, Kamran

AU - Hill, Mary A.

AU - Tzakis, Andreas G.

AU - Schiff, Eugene R

PY - 2004/5/1

Y1 - 2004/5/1

N2 - The optimal duration of therapy for pegylated interferon combined with ribavirin in recurrent Hepatitis C virus (HCV) following liver transplantation is not known. We wanted to determine if testing for HCV in liver tissue by reverse transcriptase polymerase chain reaction (RT-PCR) was superior in predicting sustained virological response (SVR) in comparison to standard HCV ribonucleic acid (RNA) detection in the serum. All recipients received combination pegylated alpha-2b interferon (1.5 mcg / kg) and ribavirin (200-600mg / d) therapy for at least 48 weeks of therapy and were found to have nondetectable HCV RNA by PCR serum testing at the end of therapy. Sustained virological response (SVR) was defined as nondetectable serum HCV RNA at 6 months post treatment withdrawal. Ten liver transplant recipients were included in the study; mean time from transplantation was 29.2 months. All had nondetectable serum HCV RNA by RT-PCR. In hepatic tissue 7/10 patients HCV RNA was found to be positive by RT-PCR while 3/10 had nondetectable HCV RNA in their liver by RT-PCR. SVR was attained in all 3/10 that were hepatic tissue HCV PCR negative after 12 months of combination therapy. In conclusion, direct detection of HCV RNA by RT-PCR of liver tissue appears to more effectively predict SVR following pegylated interferon and ribavirin therapy than the conventional use of serum.

AB - The optimal duration of therapy for pegylated interferon combined with ribavirin in recurrent Hepatitis C virus (HCV) following liver transplantation is not known. We wanted to determine if testing for HCV in liver tissue by reverse transcriptase polymerase chain reaction (RT-PCR) was superior in predicting sustained virological response (SVR) in comparison to standard HCV ribonucleic acid (RNA) detection in the serum. All recipients received combination pegylated alpha-2b interferon (1.5 mcg / kg) and ribavirin (200-600mg / d) therapy for at least 48 weeks of therapy and were found to have nondetectable HCV RNA by PCR serum testing at the end of therapy. Sustained virological response (SVR) was defined as nondetectable serum HCV RNA at 6 months post treatment withdrawal. Ten liver transplant recipients were included in the study; mean time from transplantation was 29.2 months. All had nondetectable serum HCV RNA by RT-PCR. In hepatic tissue 7/10 patients HCV RNA was found to be positive by RT-PCR while 3/10 had nondetectable HCV RNA in their liver by RT-PCR. SVR was attained in all 3/10 that were hepatic tissue HCV PCR negative after 12 months of combination therapy. In conclusion, direct detection of HCV RNA by RT-PCR of liver tissue appears to more effectively predict SVR following pegylated interferon and ribavirin therapy than the conventional use of serum.

UR - http://www.scopus.com/inward/record.url?scp=2442584768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442584768&partnerID=8YFLogxK

U2 - 10.1002/lt.20115

DO - 10.1002/lt.20115

M3 - Article

C2 - 15108250

AN - SCOPUS:2442584768

VL - 10

SP - 595

EP - 598

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 5

ER -